nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—hematopoietic system—stomach cancer	0.0112	0.0662	CbGeAlD
L-DOPA—PSIP1—lymphoid tissue—stomach cancer	0.00789	0.0466	CbGeAlD
L-DOPA—PSIP1—digestive system—stomach cancer	0.00779	0.046	CbGeAlD
L-DOPA—PSIP1—bone marrow—stomach cancer	0.00718	0.0424	CbGeAlD
L-DOPA—PSIP1—endocrine gland—stomach cancer	0.00644	0.038	CbGeAlD
L-DOPA—DRD5—hematopoietic system—stomach cancer	0.00614	0.0363	CbGeAlD
L-DOPA—SLC7A8—pancreas—stomach cancer	0.00601	0.0355	CbGeAlD
L-DOPA—PSIP1—liver—stomach cancer	0.0058	0.0343	CbGeAlD
L-DOPA—SLC7A5—hematopoietic system—stomach cancer	0.00572	0.0338	CbGeAlD
L-DOPA—SLC7A5—epithelium—stomach cancer	0.00523	0.0309	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—stomach cancer	0.00504	0.0298	CbGeAlD
L-DOPA—SLC7A5—pancreas—stomach cancer	0.00466	0.0275	CbGeAlD
L-DOPA—PSIP1—lymph node—stomach cancer	0.00445	0.0263	CbGeAlD
L-DOPA—SLC16A10—hematopoietic system—stomach cancer	0.00438	0.0259	CbGeAlD
L-DOPA—SLC15A1—epithelium—stomach cancer	0.00434	0.0257	CbGeAlD
L-DOPA—DRD5—lymphoid tissue—stomach cancer	0.00433	0.0256	CbGeAlD
L-DOPA—SLC7A8—endocrine gland—stomach cancer	0.00424	0.0251	CbGeAlD
L-DOPA—SLC7A5—lymphoid tissue—stomach cancer	0.00403	0.0238	CbGeAlD
L-DOPA—SLC16A10—epithelium—stomach cancer	0.00401	0.0237	CbGeAlD
L-DOPA—SLC7A5—digestive system—stomach cancer	0.00398	0.0235	CbGeAlD
L-DOPA—SLC7A8—liver—stomach cancer	0.00383	0.0226	CbGeAlD
L-DOPA—DDC—endocrine gland—stomach cancer	0.00367	0.0217	CbGeAlD
L-DOPA—SLC7A5—bone marrow—stomach cancer	0.00367	0.0217	CbGeAlD
L-DOPA—DRD5—endocrine gland—stomach cancer	0.00353	0.0209	CbGeAlD
L-DOPA—DDC—liver—stomach cancer	0.00331	0.0196	CbGeAlD
L-DOPA—SLC15A1—digestive system—stomach cancer	0.0033	0.0195	CbGeAlD
L-DOPA—SLC7A5—endocrine gland—stomach cancer	0.00329	0.0194	CbGeAlD
L-DOPA—SLC16A10—lymphoid tissue—stomach cancer	0.00308	0.0182	CbGeAlD
L-DOPA—SLC7A5—liver—stomach cancer	0.00296	0.0175	CbGeAlD
L-DOPA—SLC7A8—lymph node—stomach cancer	0.00293	0.0173	CbGeAlD
L-DOPA—SLC15A1—endocrine gland—stomach cancer	0.00273	0.0161	CbGeAlD
L-DOPA—DDC—lymph node—stomach cancer	0.00254	0.015	CbGeAlD
L-DOPA—SLC16A10—endocrine gland—stomach cancer	0.00252	0.0149	CbGeAlD
L-DOPA—SLC15A1—liver—stomach cancer	0.00246	0.0145	CbGeAlD
L-DOPA—Masoprocol—ALOX5—stomach cancer	0.00245	0.121	CrCbGaD
L-DOPA—Aminosalicylic Acid—ALOX5—stomach cancer	0.00228	0.113	CrCbGaD
L-DOPA—SLC7A5—lymph node—stomach cancer	0.00227	0.0134	CbGeAlD
L-DOPA—SLC16A10—liver—stomach cancer	0.00227	0.0134	CbGeAlD
L-DOPA—Isoprenaline—MAPK1—stomach cancer	0.0022	0.109	CrCbGaD
L-DOPA—Mesalazine—ALOX5—stomach cancer	0.00179	0.0884	CrCbGaD
L-DOPA—SLC16A10—lymph node—stomach cancer	0.00174	0.0103	CbGeAlD
L-DOPA—CYP2D6—hematopoietic system—stomach cancer	0.00167	0.00985	CbGeAlD
L-DOPA—DRD2—endocrine gland—stomach cancer	0.00159	0.00942	CbGeAlD
L-DOPA—Isoetarine—ADRB1—stomach cancer	0.00158	0.0782	CrCbGaD
L-DOPA—Isoetarine—ADRB2—stomach cancer	0.00133	0.0657	CrCbGaD
L-DOPA—CYP2D6—digestive system—stomach cancer	0.00116	0.00685	CbGeAlD
L-DOPA—Mesalazine—PPARG—stomach cancer	0.00102	0.0506	CrCbGaD
L-DOPA—CYP2D6—endocrine gland—stomach cancer	0.000958	0.00566	CbGeAlD
L-DOPA—CYP2D6—liver—stomach cancer	0.000863	0.0051	CbGeAlD
L-DOPA—Droxidopa—ADRB1—stomach cancer	0.000722	0.0357	CrCbGaD
L-DOPA—Isoprenaline—ADRB1—stomach cancer	0.000657	0.0325	CrCbGaD
L-DOPA—Norepinephrine—ADRB1—stomach cancer	0.000608	0.0301	CrCbGaD
L-DOPA—Droxidopa—ADRB2—stomach cancer	0.000608	0.03	CrCbGaD
L-DOPA—Dopamine—ADRB1—stomach cancer	0.000565	0.0279	CrCbGaD
L-DOPA—Isoprenaline—ADRB2—stomach cancer	0.000552	0.0273	CrCbGaD
L-DOPA—Epinephrine—ADRB1—stomach cancer	0.000552	0.0273	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—stomach cancer	0.00055	0.0272	CrCbGaD
L-DOPA—Epinephrine—TNF—stomach cancer	0.000524	0.0259	CrCbGaD
L-DOPA—Norepinephrine—ADRB2—stomach cancer	0.000511	0.0253	CrCbGaD
L-DOPA—Dopamine—HTR1A—stomach cancer	0.000506	0.025	CrCbGaD
L-DOPA—Epinephrine—ADRB2—stomach cancer	0.000464	0.0229	CrCbGaD
L-DOPA—Urinary tract disorder—Methotrexate—stomach cancer	0.000457	0.000979	CcSEcCtD
L-DOPA—Oedema—Docetaxel—stomach cancer	0.000456	0.000977	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—stomach cancer	0.000455	0.000976	CcSEcCtD
L-DOPA—Discomfort—Capecitabine—stomach cancer	0.000455	0.000975	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—stomach cancer	0.000453	0.000971	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—stomach cancer	0.000453	0.00097	CcSEcCtD
L-DOPA—Diarrhoea—Irinotecan—stomach cancer	0.000451	0.000967	CcSEcCtD
L-DOPA—Dry mouth—Capecitabine—stomach cancer	0.00045	0.000965	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—stomach cancer	0.00045	0.000964	CcSEcCtD
L-DOPA—Shock—Docetaxel—stomach cancer	0.000448	0.000961	CcSEcCtD
L-DOPA—Pruritus—Fluorouracil—stomach cancer	0.000447	0.000957	CcSEcCtD
L-DOPA—Thrombocytopenia—Docetaxel—stomach cancer	0.000446	0.000956	CcSEcCtD
L-DOPA—Confusional state—Capecitabine—stomach cancer	0.000445	0.000954	CcSEcCtD
L-DOPA—Oedema—Capecitabine—stomach cancer	0.000441	0.000946	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—stomach cancer	0.000437	0.000937	CcSEcCtD
L-DOPA—Dizziness—Irinotecan—stomach cancer	0.000436	0.000934	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—stomach cancer	0.000435	0.000932	CcSEcCtD
L-DOPA—Anorexia—Docetaxel—stomach cancer	0.000434	0.000931	CcSEcCtD
L-DOPA—Shock—Capecitabine—stomach cancer	0.000434	0.00093	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—stomach cancer	0.000434	0.00093	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—stomach cancer	0.000433	0.000929	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—stomach cancer	0.000433	0.000927	CcSEcCtD
L-DOPA—Diarrhoea—Fluorouracil—stomach cancer	0.000432	0.000926	CcSEcCtD
L-DOPA—Thrombocytopenia—Capecitabine—stomach cancer	0.000432	0.000926	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—stomach cancer	0.000432	0.0213	CrCbGaD
L-DOPA—Hypoaesthesia—Epirubicin—stomach cancer	0.000431	0.000923	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—stomach cancer	0.000427	0.000916	CcSEcCtD
L-DOPA—Hyperhidrosis—Capecitabine—stomach cancer	0.000427	0.000914	CcSEcCtD
L-DOPA—Hypotension—Docetaxel—stomach cancer	0.000426	0.000913	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—stomach cancer	0.000424	0.000909	CcSEcCtD
L-DOPA—Anorexia—Capecitabine—stomach cancer	0.000421	0.000901	CcSEcCtD
L-DOPA—Vomiting—Irinotecan—stomach cancer	0.000419	0.000898	CcSEcCtD
L-DOPA—Dizziness—Fluorouracil—stomach cancer	0.000418	0.000895	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—stomach cancer	0.000416	0.000892	CcSEcCtD
L-DOPA—Rash—Irinotecan—stomach cancer	0.000416	0.000891	CcSEcCtD
L-DOPA—Dermatitis—Irinotecan—stomach cancer	0.000415	0.00089	CcSEcCtD
L-DOPA—Headache—Irinotecan—stomach cancer	0.000413	0.000885	CcSEcCtD
L-DOPA—Hypotension—Capecitabine—stomach cancer	0.000412	0.000884	CcSEcCtD
L-DOPA—Insomnia—Docetaxel—stomach cancer	0.000412	0.000883	CcSEcCtD
L-DOPA—Paraesthesia—Docetaxel—stomach cancer	0.000409	0.000877	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—stomach cancer	0.000409	0.000876	CcSEcCtD
L-DOPA—Dyspnoea—Docetaxel—stomach cancer	0.000406	0.000871	CcSEcCtD
L-DOPA—Somnolence—Docetaxel—stomach cancer	0.000405	0.000868	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—stomach cancer	0.000405	0.000868	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—stomach cancer	0.000402	0.000862	CcSEcCtD
L-DOPA—Flushing—Epirubicin—stomach cancer	0.000402	0.000861	CcSEcCtD
L-DOPA—Vomiting—Fluorouracil—stomach cancer	0.000401	0.00086	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—stomach cancer	0.000401	0.00086	CcSEcCtD
L-DOPA—Dyspepsia—Docetaxel—stomach cancer	0.000401	0.00086	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—stomach cancer	0.0004	0.000858	CcSEcCtD
L-DOPA—Insomnia—Capecitabine—stomach cancer	0.000399	0.000855	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—stomach cancer	0.000398	0.000854	CcSEcCtD
L-DOPA—Rash—Fluorouracil—stomach cancer	0.000398	0.000853	CcSEcCtD
L-DOPA—Dermatitis—Fluorouracil—stomach cancer	0.000398	0.000852	CcSEcCtD
L-DOPA—Paraesthesia—Capecitabine—stomach cancer	0.000396	0.000849	CcSEcCtD
L-DOPA—Decreased appetite—Docetaxel—stomach cancer	0.000396	0.000849	CcSEcCtD
L-DOPA—Headache—Fluorouracil—stomach cancer	0.000396	0.000848	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—stomach cancer	0.000395	0.000847	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—stomach cancer	0.000394	0.000845	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000393	0.000843	CcSEcCtD
L-DOPA—Dyspnoea—Capecitabine—stomach cancer	0.000393	0.000843	CcSEcCtD
L-DOPA—Fatigue—Docetaxel—stomach cancer	0.000393	0.000842	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—stomach cancer	0.000392	0.000841	CcSEcCtD
L-DOPA—Nausea—Irinotecan—stomach cancer	0.000392	0.000839	CcSEcCtD
L-DOPA—Constipation—Docetaxel—stomach cancer	0.00039	0.000835	CcSEcCtD
L-DOPA—Pain—Docetaxel—stomach cancer	0.00039	0.000835	CcSEcCtD
L-DOPA—Back pain—Methotrexate—stomach cancer	0.000389	0.000834	CcSEcCtD
L-DOPA—Dyspepsia—Capecitabine—stomach cancer	0.000388	0.000832	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—stomach cancer	0.000387	0.000828	CcSEcCtD
L-DOPA—Decreased appetite—Capecitabine—stomach cancer	0.000384	0.000822	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—stomach cancer	0.000382	0.000819	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000381	0.000816	CcSEcCtD
L-DOPA—Fatigue—Capecitabine—stomach cancer	0.00038	0.000815	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—stomach cancer	0.000379	0.000813	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—stomach cancer	0.000379	0.000812	CcSEcCtD
L-DOPA—Pain—Capecitabine—stomach cancer	0.000377	0.000809	CcSEcCtD
L-DOPA—Constipation—Capecitabine—stomach cancer	0.000377	0.000809	CcSEcCtD
L-DOPA—Feeling abnormal—Docetaxel—stomach cancer	0.000376	0.000805	CcSEcCtD
L-DOPA—Nausea—Fluorouracil—stomach cancer	0.000375	0.000804	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—stomach cancer	0.000373	0.0008	CcSEcCtD
L-DOPA—Gastrointestinal pain—Docetaxel—stomach cancer	0.000373	0.000799	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—stomach cancer	0.000372	0.000797	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—stomach cancer	0.000372	0.000796	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—stomach cancer	0.000371	0.000795	CcSEcCtD
L-DOPA—Tension—Epirubicin—stomach cancer	0.00037	0.000792	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—stomach cancer	0.000369	0.00079	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—stomach cancer	0.000366	0.000784	CcSEcCtD
L-DOPA—Back pain—Epirubicin—stomach cancer	0.000364	0.000781	CcSEcCtD
L-DOPA—Feeling abnormal—Capecitabine—stomach cancer	0.000364	0.000779	CcSEcCtD
L-DOPA—Malaise—Methotrexate—stomach cancer	0.000363	0.000778	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—stomach cancer	0.000362	0.000776	CcSEcCtD
L-DOPA—Gastrointestinal pain—Capecitabine—stomach cancer	0.000361	0.000773	CcSEcCtD
L-DOPA—Abdominal pain—Docetaxel—stomach cancer	0.00036	0.000772	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—stomach cancer	0.00036	0.000772	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—stomach cancer	0.000358	0.000766	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—stomach cancer	0.000355	0.000761	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—stomach cancer	0.000354	0.000758	CcSEcCtD
L-DOPA—Cough—Methotrexate—stomach cancer	0.000351	0.000753	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—stomach cancer	0.000351	0.000752	CcSEcCtD
L-DOPA—Urticaria—Capecitabine—stomach cancer	0.000351	0.000751	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—stomach cancer	0.000349	0.000749	CcSEcCtD
L-DOPA—Abdominal pain—Capecitabine—stomach cancer	0.000349	0.000748	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—stomach cancer	0.000349	0.000747	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—stomach cancer	0.000348	0.000746	CcSEcCtD
L-DOPA—Agitation—Epirubicin—stomach cancer	0.000346	0.000742	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—stomach cancer	0.000343	0.000736	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—stomach cancer	0.000343	0.000734	CcSEcCtD
L-DOPA—Tension—Doxorubicin—stomach cancer	0.000342	0.000733	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—stomach cancer	0.000341	0.000731	CcSEcCtD
L-DOPA—Malaise—Epirubicin—stomach cancer	0.00034	0.000728	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—stomach cancer	0.000339	0.000726	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—stomach cancer	0.000338	0.000725	CcSEcCtD
L-DOPA—Syncope—Epirubicin—stomach cancer	0.000338	0.000724	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—stomach cancer	0.000337	0.000723	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—stomach cancer	0.000337	0.000722	CcSEcCtD
L-DOPA—Hypersensitivity—Docetaxel—stomach cancer	0.000336	0.00072	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—stomach cancer	0.000335	0.000718	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—stomach cancer	0.000333	0.000713	CcSEcCtD
L-DOPA—Liothyronine—ALB—stomach cancer	0.000331	0.0164	CrCbGaD
L-DOPA—Confusional state—Methotrexate—stomach cancer	0.000331	0.00071	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—stomach cancer	0.000331	0.000709	CcSEcCtD
L-DOPA—Cough—Epirubicin—stomach cancer	0.000329	0.000704	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—stomach cancer	0.000328	0.000704	CcSEcCtD
L-DOPA—Asthenia—Docetaxel—stomach cancer	0.000327	0.000701	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—stomach cancer	0.000326	0.000699	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—stomach cancer	0.000325	0.000697	CcSEcCtD
L-DOPA—Hypersensitivity—Capecitabine—stomach cancer	0.000325	0.000697	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—stomach cancer	0.000323	0.000693	CcSEcCtD
L-DOPA—Pruritus—Docetaxel—stomach cancer	0.000322	0.000691	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—stomach cancer	0.000322	0.00069	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—stomach cancer	0.000322	0.000689	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—stomach cancer	0.000321	0.000687	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—stomach cancer	0.00032	0.000686	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—stomach cancer	0.00032	0.000685	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—stomach cancer	0.000318	0.000681	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—stomach cancer	0.000317	0.000679	CcSEcCtD
L-DOPA—Asthenia—Capecitabine—stomach cancer	0.000317	0.000678	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—stomach cancer	0.000314	0.000674	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—stomach cancer	0.000314	0.000672	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—stomach cancer	0.000313	0.000671	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—stomach cancer	0.000313	0.00067	CcSEcCtD
L-DOPA—Pruritus—Capecitabine—stomach cancer	0.000312	0.000669	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—stomach cancer	0.000312	0.000669	CcSEcCtD
L-DOPA—Diarrhoea—Docetaxel—stomach cancer	0.000312	0.000668	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—stomach cancer	0.00031	0.000664	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—stomach cancer	0.000308	0.00066	CcSEcCtD
L-DOPA—Oedema—Epirubicin—stomach cancer	0.000307	0.000659	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—stomach cancer	0.000307	0.000658	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—stomach cancer	0.000306	0.000656	CcSEcCtD
L-DOPA—Cough—Doxorubicin—stomach cancer	0.000304	0.000652	CcSEcCtD
L-DOPA—Shock—Epirubicin—stomach cancer	0.000302	0.000648	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—stomach cancer	0.000302	0.000647	CcSEcCtD
L-DOPA—Diarrhoea—Capecitabine—stomach cancer	0.000302	0.000647	CcSEcCtD
L-DOPA—Dizziness—Docetaxel—stomach cancer	0.000301	0.000646	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—stomach cancer	0.000301	0.000645	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—stomach cancer	0.000301	0.000645	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—stomach cancer	0.000297	0.000637	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—stomach cancer	0.000297	0.000637	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—stomach cancer	0.000297	0.000636	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—stomach cancer	0.000296	0.000634	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—stomach cancer	0.000295	0.000632	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—stomach cancer	0.000293	0.000628	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—stomach cancer	0.000293	0.000628	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—stomach cancer	0.000293	0.000628	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—stomach cancer	0.000292	0.000626	CcSEcCtD
L-DOPA—Dizziness—Capecitabine—stomach cancer	0.000292	0.000625	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—stomach cancer	0.00029	0.000622	CcSEcCtD
L-DOPA—Vomiting—Docetaxel—stomach cancer	0.00029	0.000621	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—stomach cancer	0.000289	0.00062	CcSEcCtD
L-DOPA—Rash—Docetaxel—stomach cancer	0.000287	0.000616	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—stomach cancer	0.000287	0.000616	CcSEcCtD
L-DOPA—Dermatitis—Docetaxel—stomach cancer	0.000287	0.000615	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—stomach cancer	0.000287	0.000615	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—stomach cancer	0.000286	0.000612	CcSEcCtD
L-DOPA—Headache—Docetaxel—stomach cancer	0.000286	0.000612	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—stomach cancer	0.000284	0.00061	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000284	0.000608	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—stomach cancer	0.000283	0.000607	CcSEcCtD
L-DOPA—Pain—Methotrexate—stomach cancer	0.000281	0.000602	CcSEcCtD
L-DOPA—Vomiting—Capecitabine—stomach cancer	0.000281	0.000601	CcSEcCtD
L-DOPA—Shock—Doxorubicin—stomach cancer	0.00028	0.0006	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—stomach cancer	0.000278	0.000597	CcSEcCtD
L-DOPA—Rash—Capecitabine—stomach cancer	0.000278	0.000596	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—stomach cancer	0.000278	0.000596	CcSEcCtD
L-DOPA—Dermatitis—Capecitabine—stomach cancer	0.000278	0.000596	CcSEcCtD
L-DOPA—Headache—Capecitabine—stomach cancer	0.000276	0.000592	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—stomach cancer	0.000276	0.000592	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—stomach cancer	0.000275	0.000589	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—stomach cancer	0.000274	0.000587	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—stomach cancer	0.000273	0.000586	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—stomach cancer	0.000271	0.000581	CcSEcCtD
L-DOPA—Nausea—Docetaxel—stomach cancer	0.000271	0.00058	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—stomach cancer	0.000271	0.00058	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—stomach cancer	0.000271	0.00058	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—stomach cancer	0.000269	0.000576	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—stomach cancer	0.000267	0.000573	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—stomach cancer	0.000266	0.00057	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000265	0.000569	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—stomach cancer	0.000265	0.000568	CcSEcCtD
L-DOPA—Constipation—Epirubicin—stomach cancer	0.000263	0.000563	CcSEcCtD
L-DOPA—Pain—Epirubicin—stomach cancer	0.000263	0.000563	CcSEcCtD
L-DOPA—Nausea—Capecitabine—stomach cancer	0.000262	0.000562	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—stomach cancer	0.000261	0.000559	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—stomach cancer	0.00026	0.000557	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—stomach cancer	0.000257	0.000551	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—stomach cancer	0.000255	0.000547	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—stomach cancer	0.000254	0.000543	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—stomach cancer	0.000253	0.000543	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—stomach cancer	0.000253	0.000542	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—stomach cancer	0.000251	0.000539	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—stomach cancer	0.00025	0.000537	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—stomach cancer	0.000247	0.00053	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000246	0.000526	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—stomach cancer	0.000245	0.000526	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—stomach cancer	0.000244	0.000523	CcSEcCtD
L-DOPA—Pain—Doxorubicin—stomach cancer	0.000243	0.000521	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—stomach cancer	0.000243	0.000521	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—stomach cancer	0.000243	0.000521	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—stomach cancer	0.000242	0.000519	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—stomach cancer	0.000236	0.000505	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—stomach cancer	0.000234	0.000502	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000233	0.000498	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—stomach cancer	0.000232	0.000498	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—stomach cancer	0.000226	0.000485	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—stomach cancer	0.000226	0.000484	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—stomach cancer	0.000225	0.000482	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—stomach cancer	0.000225	0.000482	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—stomach cancer	0.000221	0.000473	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—stomach cancer	0.000217	0.000466	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—stomach cancer	0.000217	0.000466	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—stomach cancer	0.00021	0.000451	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—stomach cancer	0.00021	0.000449	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—stomach cancer	0.000209	0.000448	CcSEcCtD
L-DOPA—Rash—Methotrexate—stomach cancer	0.000207	0.000444	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—stomach cancer	0.000207	0.000443	CcSEcCtD
L-DOPA—Headache—Methotrexate—stomach cancer	0.000206	0.000441	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—stomach cancer	0.000204	0.000437	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—stomach cancer	0.000203	0.000436	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—stomach cancer	0.000201	0.000431	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—stomach cancer	0.000195	0.000419	CcSEcCtD
L-DOPA—Nausea—Methotrexate—stomach cancer	0.000195	0.000418	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—stomach cancer	0.000195	0.000417	CcSEcCtD
L-DOPA—Rash—Epirubicin—stomach cancer	0.000194	0.000415	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—stomach cancer	0.000194	0.000415	CcSEcCtD
L-DOPA—Headache—Epirubicin—stomach cancer	0.000193	0.000413	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—stomach cancer	0.000188	0.000403	CcSEcCtD
L-DOPA—Nausea—Epirubicin—stomach cancer	0.000183	0.000391	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—stomach cancer	0.000181	0.000388	CcSEcCtD
L-DOPA—Rash—Doxorubicin—stomach cancer	0.000179	0.000384	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—stomach cancer	0.000179	0.000384	CcSEcCtD
L-DOPA—Headache—Doxorubicin—stomach cancer	0.000178	0.000382	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—stomach cancer	0.000169	0.000362	CcSEcCtD
L-DOPA—DRD1—GPCR downstream signaling—RHOA—stomach cancer	3.49e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—F2R—stomach cancer	3.48e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BMP2—stomach cancer	3.48e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6R—stomach cancer	3.46e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—RHOA—stomach cancer	3.45e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMAD4—stomach cancer	3.44e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKR1C3—stomach cancer	3.43e-05	9.97e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—stomach cancer	3.4e-05	9.9e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADRB2—stomach cancer	3.4e-05	9.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR1A—stomach cancer	3.39e-05	9.86e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APC—stomach cancer	3.36e-05	9.77e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADRB2—stomach cancer	3.36e-05	9.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PPP2R1A—stomach cancer	3.34e-05	9.7e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SREBF2—stomach cancer	3.32e-05	9.65e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PPP2R1A—stomach cancer	3.29e-05	9.57e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PRKCB—stomach cancer	3.28e-05	9.55e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—RORA—stomach cancer	3.28e-05	9.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ANXA1—stomach cancer	3.28e-05	9.52e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FYN—stomach cancer	3.27e-05	9.5e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK3—stomach cancer	3.22e-05	9.36e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRB1—stomach cancer	3.17e-05	9.22e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RHOA—stomach cancer	3.17e-05	9.22e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RHOA—stomach cancer	3.13e-05	9.1e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6R—stomach cancer	3.12e-05	9.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMAD4—stomach cancer	3.1e-05	9.01e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—stomach cancer	3.09e-05	8.99e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALDOB—stomach cancer	3.07e-05	8.94e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGFR2—stomach cancer	3.07e-05	8.92e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—stomach cancer	3.07e-05	8.91e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK1—stomach cancer	3.06e-05	8.9e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—stomach cancer	3.06e-05	8.9e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMAD4—stomach cancer	3.06e-05	8.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RPS6—stomach cancer	3.03e-05	8.81e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—stomach cancer	3.02e-05	8.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PRKCB—stomach cancer	2.98e-05	8.67e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6ST—stomach cancer	2.97e-05	8.64e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FYN—stomach cancer	2.94e-05	8.55e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CA—stomach cancer	2.93e-05	8.51e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SERPINE1—stomach cancer	2.92e-05	8.5e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FYN—stomach cancer	2.9e-05	8.44e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—stomach cancer	2.89e-05	8.41e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALOX5—stomach cancer	2.86e-05	8.31e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RHOA—stomach cancer	2.82e-05	8.2e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—DPYD—stomach cancer	2.81e-05	8.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IRS2—stomach cancer	2.81e-05	8.17e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOS3—stomach cancer	2.79e-05	8.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HBEGF—stomach cancer	2.79e-05	8.1e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—stomach cancer	2.78e-05	8.09e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGFR2—stomach cancer	2.76e-05	8.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—stomach cancer	2.75e-05	7.98e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGFR2—stomach cancer	2.72e-05	7.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CAV1—stomach cancer	2.72e-05	7.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOA1—stomach cancer	2.72e-05	7.9e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—stomach cancer	2.66e-05	7.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6R—stomach cancer	2.65e-05	7.7e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—RHOA—stomach cancer	2.64e-05	7.66e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—stomach cancer	2.61e-05	7.59e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PRKCB—stomach cancer	2.59e-05	7.54e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6ST—stomach cancer	2.58e-05	7.51e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRB2—stomach cancer	2.57e-05	7.47e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IRS2—stomach cancer	2.53e-05	7.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PPP2R1A—stomach cancer	2.52e-05	7.32e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IRS2—stomach cancer	2.49e-05	7.25e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTT1—stomach cancer	2.49e-05	7.23e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APC—stomach cancer	2.48e-05	7.21e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—stomach cancer	2.47e-05	7.2e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—stomach cancer	2.46e-05	7.15e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2A6—stomach cancer	2.46e-05	7.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CAV1—stomach cancer	2.45e-05	7.13e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOA1—stomach cancer	2.45e-05	7.11e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CAV1—stomach cancer	2.42e-05	7.03e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1B—stomach cancer	2.42e-05	7.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOA1—stomach cancer	2.41e-05	7.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RHOA—stomach cancer	2.39e-05	6.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKR1C3—stomach cancer	2.39e-05	6.95e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—stomach cancer	2.39e-05	6.95e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK3—stomach cancer	2.38e-05	6.91e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—stomach cancer	2.35e-05	6.84e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMAD4—stomach cancer	2.34e-05	6.8e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PRKCB—stomach cancer	2.33e-05	6.78e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO1—stomach cancer	2.33e-05	6.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6ST—stomach cancer	2.32e-05	6.76e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—stomach cancer	2.31e-05	6.73e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—stomach cancer	2.31e-05	6.7e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6R—stomach cancer	2.3e-05	6.7e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PRKCB—stomach cancer	2.3e-05	6.69e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—stomach cancer	2.3e-05	6.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6ST—stomach cancer	2.29e-05	6.67e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK1—stomach cancer	2.26e-05	6.57e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—stomach cancer	2.26e-05	6.57e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—stomach cancer	2.24e-05	6.51e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APC—stomach cancer	2.23e-05	6.49e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1A—stomach cancer	2.23e-05	6.48e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FYN—stomach cancer	2.22e-05	6.46e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—stomach cancer	2.2e-05	6.41e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK8—stomach cancer	2.18e-05	6.33e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—stomach cancer	2.16e-05	6.28e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SERPINE1—stomach cancer	2.16e-05	6.27e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK3—stomach cancer	2.14e-05	6.22e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—stomach cancer	2.13e-05	6.21e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK3—stomach cancer	2.11e-05	6.13e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—stomach cancer	2.1e-05	6.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR2—stomach cancer	2.08e-05	6.06e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RHOA—stomach cancer	2.08e-05	6.05e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6R—stomach cancer	2.07e-05	6.03e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CD44—stomach cancer	2.07e-05	6.01e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—stomach cancer	2.06e-05	5.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6R—stomach cancer	2.05e-05	5.95e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK1—stomach cancer	2.03e-05	5.92e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—stomach cancer	2.03e-05	5.91e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—stomach cancer	2.01e-05	5.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK1—stomach cancer	2.01e-05	5.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—stomach cancer	2.01e-05	5.84e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—stomach cancer	1.99e-05	5.79e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—stomach cancer	1.96e-05	5.7e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—stomach cancer	1.94e-05	5.65e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SERPINE1—stomach cancer	1.94e-05	5.65e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—stomach cancer	1.93e-05	5.6e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—stomach cancer	1.92e-05	5.59e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—stomach cancer	1.92e-05	5.58e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SERPINE1—stomach cancer	1.92e-05	5.57e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IRS2—stomach cancer	1.91e-05	5.55e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK3—stomach cancer	1.9e-05	5.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—stomach cancer	1.9e-05	5.51e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RHOA—stomach cancer	1.87e-05	5.45e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—stomach cancer	1.85e-05	5.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CAV1—stomach cancer	1.85e-05	5.38e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—stomach cancer	1.85e-05	5.38e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RHOA—stomach cancer	1.85e-05	5.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOA1—stomach cancer	1.85e-05	5.37e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—stomach cancer	1.83e-05	5.32e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—stomach cancer	1.83e-05	5.31e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—stomach cancer	1.81e-05	5.28e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK1—stomach cancer	1.81e-05	5.26e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—stomach cancer	1.81e-05	5.26e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1B—stomach cancer	1.78e-05	5.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—stomach cancer	1.77e-05	5.13e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCB—stomach cancer	1.76e-05	5.12e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPP2R1A—stomach cancer	1.76e-05	5.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6ST—stomach cancer	1.75e-05	5.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—stomach cancer	1.74e-05	5.07e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—stomach cancer	1.74e-05	5.05e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—stomach cancer	1.73e-05	5.04e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—stomach cancer	1.72e-05	5.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—stomach cancer	1.71e-05	4.97e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—stomach cancer	1.71e-05	4.97e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—stomach cancer	1.7e-05	4.95e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—stomach cancer	1.7e-05	4.94e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—stomach cancer	1.7e-05	4.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—stomach cancer	1.69e-05	4.9e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—stomach cancer	1.65e-05	4.8e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1A—stomach cancer	1.65e-05	4.79e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—stomach cancer	1.64e-05	4.78e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—stomach cancer	1.63e-05	4.75e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—stomach cancer	1.62e-05	4.72e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK3—stomach cancer	1.61e-05	4.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—stomach cancer	1.61e-05	4.69e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK8—stomach cancer	1.61e-05	4.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1B—stomach cancer	1.61e-05	4.67e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMS—stomach cancer	1.6e-05	4.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1B—stomach cancer	1.58e-05	4.61e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—stomach cancer	1.58e-05	4.61e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—stomach cancer	1.57e-05	4.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6R—stomach cancer	1.57e-05	4.55e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—stomach cancer	1.56e-05	4.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—stomach cancer	1.54e-05	4.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK1—stomach cancer	1.54e-05	4.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—stomach cancer	1.54e-05	4.47e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—stomach cancer	1.53e-05	4.45e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—stomach cancer	1.53e-05	4.44e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—stomach cancer	1.52e-05	4.42e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—stomach cancer	1.51e-05	4.39e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—stomach cancer	1.51e-05	4.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ERCC2—stomach cancer	1.49e-05	4.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—stomach cancer	1.49e-05	4.32e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—stomach cancer	1.48e-05	4.31e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1A—stomach cancer	1.48e-05	4.31e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—stomach cancer	1.47e-05	4.27e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—stomach cancer	1.47e-05	4.27e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—stomach cancer	1.47e-05	4.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SERPINE1—stomach cancer	1.47e-05	4.26e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1A—stomach cancer	1.46e-05	4.25e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—stomach cancer	1.45e-05	4.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—stomach cancer	1.45e-05	4.22e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK8—stomach cancer	1.45e-05	4.21e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK8—stomach cancer	1.43e-05	4.15e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RHOA—stomach cancer	1.41e-05	4.11e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK3—stomach cancer	1.4e-05	4.08e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—stomach cancer	1.4e-05	4.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—stomach cancer	1.4e-05	4.07e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—stomach cancer	1.39e-05	4.04e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—stomach cancer	1.36e-05	3.97e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—stomach cancer	1.34e-05	3.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK1—stomach cancer	1.34e-05	3.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—stomach cancer	1.34e-05	3.88e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—stomach cancer	1.33e-05	3.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—stomach cancer	1.32e-05	3.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—stomach cancer	1.32e-05	3.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—stomach cancer	1.31e-05	3.81e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—stomach cancer	1.3e-05	3.79e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAV1—stomach cancer	1.29e-05	3.75e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOA1—stomach cancer	1.29e-05	3.75e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK3—stomach cancer	1.26e-05	3.67e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—stomach cancer	1.26e-05	3.67e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK3—stomach cancer	1.25e-05	3.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—stomach cancer	1.24e-05	3.61e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—stomach cancer	1.23e-05	3.59e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—stomach cancer	1.23e-05	3.57e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1B—stomach cancer	1.21e-05	3.52e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—stomach cancer	1.21e-05	3.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK1—stomach cancer	1.2e-05	3.49e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—stomach cancer	1.2e-05	3.49e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK1—stomach cancer	1.19e-05	3.45e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—stomach cancer	1.19e-05	3.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—stomach cancer	1.18e-05	3.43e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—stomach cancer	1.16e-05	3.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—stomach cancer	1.16e-05	3.36e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—stomach cancer	1.15e-05	3.36e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—stomach cancer	1.14e-05	3.3e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—stomach cancer	1.14e-05	3.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—stomach cancer	1.12e-05	3.26e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—stomach cancer	1.12e-05	3.26e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—stomach cancer	1.12e-05	3.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1A—stomach cancer	1.12e-05	3.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK8—stomach cancer	1.09e-05	3.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—stomach cancer	1.07e-05	3.12e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—stomach cancer	1.04e-05	3.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—stomach cancer	1.03e-05	2.99e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—stomach cancer	1.03e-05	2.98e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—stomach cancer	1.02e-05	2.97e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—stomach cancer	1.01e-05	2.93e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—stomach cancer	1.01e-05	2.93e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—stomach cancer	9.98e-06	2.9e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—stomach cancer	9.96e-06	2.89e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—stomach cancer	9.76e-06	2.84e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—stomach cancer	9.65e-06	2.81e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK3—stomach cancer	9.54e-06	2.77e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—stomach cancer	9.52e-06	2.77e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—stomach cancer	9.28e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—stomach cancer	9.24e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—stomach cancer	9.11e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK1—stomach cancer	9.08e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—stomach cancer	9.07e-06	2.64e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—stomach cancer	8.93e-06	2.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—stomach cancer	8.57e-06	2.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—stomach cancer	7.88e-06	2.29e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—stomach cancer	7.62e-06	2.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—stomach cancer	7.29e-06	2.12e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—stomach cancer	6.97e-06	2.03e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—stomach cancer	5.49e-06	1.6e-05	CbGpPWpGaD
